Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

EHC

Consider Our Overview Before Taking a Position in EHC

Large-cap Health Care company Encompass Health has logged a -0.0% change today on a trading volume of 76,681. The average volume for the stock is 755,890.

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. Based in Birmingham, United States the company has 28,851 full time employees and a market cap of $10,716,007,424. Encompass Health currently offers its equity investors a dividend that yields 0.7% per year.

The company is now trading -24.19% away from its average analyst target price of $140.33 per share. The 12 analysts following the stock have set target prices ranging from $125.0 to $160.0, and on average give Encompass Health a rating of buy.

Over the last 52 weeks, EHC stock has risen 7.8%, which amounts to a -6.0% difference compared to the S&P 500. The stock's 52 week high is $127.99 whereas its 52 week low is $87.85 per share. Based on Encompass Health's average net margin growth of 1.0% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2024 5,373,200 455,700 8 14.29
2023 4,801,200 352,000 7 16.67
2022 4,348,600 271,000 6 -40.0
2021 4,014,900 412,200 10 25.0
2020 3,566,300 284,200 8 0.0
2019 4,605,000 358,700 8
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS